'Imfinzi' shown to be effective for liver cancer
By Son, Hyung-Min | translator Kang, Shin-Kook
24.05.17 05:05:04
가나다라
0
Imfinzi plus Imjudo combination therapy confirmed efficacy as a 1st-line therapy for liver cancer
“Combination therapy has reduced risk of bleeding…more use for liver cancer”
▲Hong Jae Chon, Professor of the Department of Hemato-Oncology at CHA Bundang Medical Center
Imfinzi, an immunotherapy treatment for cancer, demonstrated effectiveness for liver cancer in addition to bile duct cancer. Consequently, it is expanding its uses in gastrointestinal cancer. AstraZeneca confirmed the effectiveness of Imfinzi in combination therapy with Imjudo, which targets CTL-A4, as a first-line treatment for liver cancer. The medical experts analyzed that this combination therapy has given hope for extended survival in patients with liver cancer.
AstraZeneca hosted a press conference at Grand InterContinental Seoul Parnas on May 14th to commemorate the launch of a combination therapy, Imfinzi plus Imjudo.
AstraZeneca’s Imfinzi is an immunotherapy for cancer
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)